Navigation Links
Cancer Drug Gleevec Linked to Muscle Damage
Date:6/18/2008

French researchers say the problem can probably strike small percentage of patients

WEDNESDAY, June 18 (HealthDay News) -- French doctors have reported a possible new side effect associated with the cancer drug Gleevec (imatinib), widely used for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors.

In a letter published in the June 19 issue of the New England Journal of Medicine, the doctors describe the case of a 25-year-old woman who developed severe rhabdomyolysis while taking imatinib.

Rhabdomyolysis is the breakdown of muscle fibers resulting in the release of muscle fiber contents (myoglobin) into the bloodstream. The condition can cause kidney damage.

The woman was taking imatinib (daily dose of 400 mg) in a clinical trial for the treatment of aggressive fibromatosis (desmoid tumors) that couldn't be treated with surgery. Shortly after the start of drug treatment, the woman experienced symptoms of rhabdomyolysis.

After she stopped taking imatinib, her symptoms ceased. She then agreed to take the drug again while under medical surveillance. Twenty-four hours after she received the first daily dose of 100 mg, she suffered severe symptoms. The drug treatment was halted, and her symptoms disappeared in three days.

The woman's desmoid tumors were treated with radiotherapy, and she has not experienced any recurrence of rhabdomyolysis symptoms.

"We considered our patient's rhabdomyolysis to be induced by imatinib because of the temporal relationship (the rhabdomyolysis occurred within a few days after the initiation of imatinib therapy), the recurrence of rhabdomyolysis with the reintroduction of the drug, and normalization of the creatine kinase level after discontinuation of the drug. Although there is extensive clinical experience with the safe use of imatinib, this observation suggests that the drug may cause severe rhabdomyolysis in a small propor
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved

Page: 1 2

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Survival differences by race most apparent in advanced stages of breast cancer
3. MRI finds breast cancer before it becomes dangerous
4. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
5. Pathway links inflammation, angiogenesis and breast cancer
6. Radiologists encouraged to look beyond cancer for clinically unseen diseases
7. Diet high in meat, fat and refined grains linked to risk for colon cancer recurrence, death
8. Immune deficiency linked to a type of eye cancer
9. Drop in breast cancer incidence linked to hormone use, not mammograms
10. Breast cancer prevention practices vary across Canada
11. First biomarker discovered that predicts prostate cancer outcome
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Circassia Raises GBP15 Million ($25 Million) in Oversubscribed Investment Round 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 2Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 4Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 5Duke University Health System Chooses SSI for Revenue Cycle Claims Management 47794 1Duke University Health System Chooses SSI for Revenue Cycle Claims Management 47794 2Duke University Health System Chooses SSI for Revenue Cycle Claims Management 47794 3Five Cord Blood Transplant Centers in Catalonia and Valencia Join a Study to Test a New Technique to Treat Leukemia and Lymphoma 12449 1Five Cord Blood Transplant Centers in Catalonia and Valencia Join a Study to Test a New Technique to Treat Leukemia and Lymphoma 12449 2Five Cord Blood Transplant Centers in Catalonia and Valencia Join a Study to Test a New Technique to Treat Leukemia and Lymphoma 12449 3Lupus Foundation of America Fosters the Next Generation of Lupus Researchers by Awarding Gina M Finzi Memorial Student Summer Fellowships to Five Stu 4531 1Lupus Foundation of America Fosters the Next Generation of Lupus Researchers by Awarding Gina M Finzi Memorial Student Summer Fellowships to Five Stu 4531 2Lupus Foundation of America Fosters the Next Generation of Lupus Researchers by Awarding Gina M Finzi Memorial Student Summer Fellowships to Five Stu 4531 3